34 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
1 Jun 23
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
7:07am
and the safety of the 3 mg twice daily dose of Piclidenoson are accepted by the agency.
Can-Fite has submitted a comparable data package to the U.S. Food
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
10 Apr 23
Report of Foreign Private Issuer
7:06am
-Fite is currently submitting a comparable data package to the US Food and Drug Administration.
Can-Fite recently reported topline results from its
424B3
u883iqzto3u 8zc6
1 Jun 20
Prospectus supplement
7:23am
6-K
EX-99.2
82pyga
1 Jun 20
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
uuh3th gkxav75hexuz
1 Jun 20
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
z6cys
13 Feb 20
Notice of Special General Meeting of Shareholders
4:30pm
424B4
eua jfgv8o65wuuftj70
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
enx5qsqy
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
zvwym 77ug
24 Jan 20
Registration statement (foreign)
4:40pm
6-K
EX-99.1
aqy7nf
9 Jan 20
Notice of Special General Meeting of Shareholders
4:41pm
20-F/A
fq8109brbcz1atp 2zap
2 Apr 19
Annual report (foreign) (amended)
6:52am
424B3
9qkv3ynxm
22 Mar 19
Prospectus supplement
4:50pm
F-1/A
z6m6 g1kvf
12 Mar 19
Registration statement (foreign) (amended)
4:20pm
F-1
g68el 8kfj
15 Feb 19
Registration statement (foreign)
4:32pm